Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 173.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (44.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.5% (LTM)
  • Share price is 244.5% higher than minimum and 3.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (39.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $78 905.9 mln (-0.379% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-0.6%)1070.25
year average price 819.99  


year start price 767.76 2024-12-24

min close price 625.65 2025-08-08

max close price 1109.94 2025-11-25

current price 1076.48 2025-12-23
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 39.9x
EV / EBITDA annualized: 32.0x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 963 873
Net Debt ($m): 32 651
EV (Enterprise Value): 996 524
EBITDA LTM ($m): 24 974
EV / LTM EBITDA: 39.9x
Price to Book: 40.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-23barrons.com

Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

2025-12-19benzinga.com

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026

2025-12-17reuters.com

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

2025-12-17marketwatch.com

Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.

2025-12-16cnbc.com

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

2025-12-15seekingalpha.com

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

2025-12-15fool.com

Eli Lilly Just Delivered Fantastic News to Investors

2025-12-13seekingalpha.com

Eli Lilly: The Right Long-Term Strategy

2025-12-12zacks.com

Why the Market Dipped But Eli Lilly (LLY) Gained Today

2025-12-12prnewswire.com

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data